Cited 0 times in
A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 형우진 | - |
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 안지영 | - |
dc.contributor.author | 이성숙 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.date.accessioned | 2014-12-19T16:59:14Z | - |
dc.date.available | 2014-12-19T16:59:14Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0167-6997 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90567 | - |
dc.description.abstract | BACKGROUND: Although its efficacy is unproven, 5-fluorouracil plus cisplatin (FP) is used to prevent postoperative relapse in gastric cancer. We investigated the safety and feasibility of S-1 plus cisplatin (SP) vs. FP for stage IIIB-IV (M0) gastric cancer. METHODS: Following curative resection, 41 stage IIIB-IV (M0) gastric cancer patients were assigned to SP (eight 14-day cycles of S-1 [40 mg/m(2) twice daily] plus cisplatin [60 mg/m(2) day 1] administered every 3 weeks) or FP (six 3-day cycles of FU [1 g/m(2) per day] plus cisplatin [80 mg/m(2) day 1] every 4 weeks). Doses were reduced based on predefined criteria. RESULTS: Patient characteristics were balanced between the two arms. In total, 124 cycles of SP (N = 20, median = 7, range 1-8) and 113 cycles of FP (N = 21, median 6, range 1-6) were administered. The median relative dose intensity per patient was 75% (49.99-100%) for S-1, 100% (75-100%) for cisplatin in SP, and 100% (64-100%) for 5-FU, 100% (60-100%) for cisplatin in FP. The relative dose intensity of FP was stable, while that of SP decreased during treatment. After median follow-up of 7.9 months (3.8-14.55), the median RFS was not reached. Relapse occurred in two (10%) patients on SP and five (23.8%) in the FP arm (P = 0.24). The incidence of grade 3-4 granulocytopenia was 36.8% with SP and 14.3% with FP. Grade 3-4 non-hematologic toxicities included fatigue (5.2% with SP vs. 4.8% with FP), vomiting (10.5% with SP vs. 0% with FP), and infection (5.2% with SP vs. 0% FP). CONCLUSION: S-1 plus cisplatin was feasible and tolerable as adjuvant treatment for stage IIIB-IV (M0) gastric cancer. However, because of decreased relative dose intensity during treatment, further study is warranted to determine optimal dosage and combination. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 357~363 | - |
dc.relation.isPartOf | INVESTIGATIONAL NEW DRUGS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/drug therapy* | - |
dc.subject.MESH | Adenocarcinoma/pathology | - |
dc.subject.MESH | Adenocarcinoma/surgery* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Chi-Square Distribution | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Feasibility Studies | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Gastrectomy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Oxonic Acid/administration & dosage | - |
dc.subject.MESH | Pilot Projects | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.subject.MESH | Stomach Neoplasms/surgery* | - |
dc.subject.MESH | Tegafur/administration & dosage | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Sung Sook Lee | - |
dc.contributor.googleauthor | Hei-Cheul Jeung | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Sung Hoon Noh | - |
dc.contributor.googleauthor | Woo Jin Hyung | - |
dc.contributor.googleauthor | Ji Yeong Ahn | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.identifier.doi | 20734110 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04382 | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A02867 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03794 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J01184 | - |
dc.identifier.eissn | 1573-0646 | - |
dc.identifier.pmid | 20734110 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs10637-010-9515-2 | - |
dc.subject.keyword | S-1 | - |
dc.subject.keyword | Stage IIIB-IV (M0) | - |
dc.subject.keyword | Gastric cancer | - |
dc.contributor.alternativeName | Hyung, Woo Jin | - |
dc.contributor.alternativeName | Noh, Sung Hoon | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | An, Ji Yeong | - |
dc.contributor.alternativeName | Lee, Sung Sook | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Hyung, Woo Jin | - |
dc.contributor.affiliatedAuthor | Noh, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Sung Sook | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 30 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 357 | - |
dc.citation.endPage | 363 | - |
dc.identifier.bibliographicCitation | INVESTIGATIONAL NEW DRUGS, Vol.30(1) : 357-363, 2012 | - |
dc.identifier.rimsid | 32838 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.